TNF and cancer: A large study from the British Society for Rheumatology Biologics Register (BSRBR) analyzing 11,767 RA patients without prior cancer who received TNF inhibitors found that the rates of solid cancers are comparable to those in 3249 patients without prior cancer treated with non-biologic (synthetic) DMARD HR 0.83 (95% CI 0.64 to 1.07).